Apollomics
Latest round
- Series B
Last raised
- Jan 2026
Total raised
- Undisclosed
Investors
- 1
About Apollomics
Founded in 2016 and headquartered in Nanjing, China, Nanjing Apollomics Biotech Inc. focuses on developing innovative biochemical products. The company has not undergone any noted pivots or changes in its business strategy since its inception. The founder's history and details on other companies are not publicly available. Apollomics' primary offerings revolve around a comprehensive range of biochemical products designed for protein quantification and analysis. Their core products include stable isotope-labeled internal standards, amino acids, hormones, therapeutic drugs, and various assays for water-soluble and fat-soluble vitamins. These products serve critical applications in clinical diagnostics, pharmaceutical research, and nutrition science, helping laboratories and researchers accurately measure biomolecules in various samples. The company's clientele includes academic institutions, research organizations, and biotechnology firms across global markets such as North America, Europe, and Asia, where they address the growing need for precise analytical tools in life sciences. Apollomics generates revenue through a structure that primarily focuses on B2B transactions with research institutions and pharmaceutical companies. Their sales model includes direct sales of products and potential partnership agreements with research entities. Revenue streams are diversified across their flagship product lines, which include proprietary assays and stable isotope standards that cater to specific research needs. The pricing strategy is tailored to reflect the specialized nature of their offerings, ensuring that clients receive high-quality, scientifically validated products. These transactions typically involve bulk orders that facilitate long-term collaborations, allowing customers access to essential resources for ongoing research and development projects.
Who invested in Apollomics
1 investor across 1 round
See all investors in Apollomics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 9, 2026
Amount
Undisclosed
Investors
Questions about Apollomics
Who invested in Apollomics?
Apollomics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Apollomics raised?
Apollomics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Apollomics last raise money?
Apollomics's most recent round on record is a Series B, in Jan 2026.
What does Apollomics do?
Founded in 2016 and headquartered in Nanjing, China, Nanjing Apollomics Biotech Inc.
Where is Apollomics headquartered?
Apollomics is headquartered in Nanjing, China.
Which VCs invest in companies like Apollomics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Apollomics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Apollomics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.